Determining the antiviral properties and mechanism of actions of BOLD-100 against SARS-CoV-2 in 2D and 3D cell culture systems

BOLD-100 is a promising new clinical stage therapeutic, originally developed for the use as a cancer treatment. The mechanism of action for BOLD-100 suggests that this therapeutic might also protect against infections with viruses, including coronaviruses like SARS-COV-19. The purpose of this project is to test the antiviral efficacy of BOLD-100 against SARS·COV-19 in 20 and 30 cell culture models, and then investigate the mechanism of action. These results will help define BOLD-100 as an antiviral treatment and support clinical investigations into BOLD-100 for the treatment of COVID-19.

Faculty Supervisor:

François Jean

Student:

Amy Short

Partner:

Bold Therapeutics

Discipline:

Biology

Sector:

Professional, scientific and technical services

University:

University of British Columbia

Program:

Accelerate

Related projects

Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.

View all
Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Find Projects

Mitacs Partners

The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.

Government
Academic
Industry
Innovation

International

Load More

International

Load More

Join a thriving innovation ecosystem.

Subscribe to our newsletter now!

Subscribe
Canada